Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Heiko, Becker"'
Autor:
Johanna Thomas, Usama-Ur Rehman, Helena Bresser, Olga Grishina, Dietmar Pfeifer, Etienne Sollier, Konstanze Döhner, Christoph Plass, Heiko Becker, Claudia Schmoor, Maike de Wit, Michael Lübbert
Publikováno v:
Clinical Epigenetics, Vol 16, Iss 1, Pp 1-5 (2024)
Abstract DNA-hypomethylating agents (HMAs) induce notable remission rates in AML/MDS patients with TP53 mutations; however, secondary resistance often develops rapidly. In the DECIDER trial (NCT00867672), elderly AML patients (also those with adverse
Externí odkaz:
https://doaj.org/article/1be44a233b44476594d325965bb4fbac
Autor:
Julia C. Kuehn, Patrick Metzger, Nicolas Neidert, Uta Matysiak, Linda Gräßel, Ulrike Philipp, Sabine Bleul, Thomas Pauli, Julia Falkenstein, Henriette Bertemes, Stepan Cysar, Maria Elena Hess, Anna Verena Frey, Jesús Duque-Afonso, Elisabeth Schorb, Marcia Machein, Jürgen Beck, Oliver Schnell, Nikolas von Bubnoff, Anna L. Illert, Christoph Peters, Tilman Brummer, Marco Prinz, Cornelius Miething, Heiko Becker, Silke Lassmann, Martin Werner, Melanie Börries, Justus Duyster, Dieter H. Heiland, Roman Sankowski, Florian Scherer
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract Despite major advances in molecular profiling and classification of primary brain tumors, personalized treatment remains limited for most patients. Here, we explored the feasibility of individual molecular profiling and the efficacy of bioma
Externí odkaz:
https://doaj.org/article/1dc07143d8964d58a48d87e8eab4e848
Autor:
Nora Rebeka Javorniczky, Olga Grishina, Inga Hund, Milena Pantic, Dietmar Pfeifer, Claudia Schmoor, Johanna Thomas, Justus Duyster, Heiko Becker, Michael Lübbert
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-5 (2023)
Abstract Elderly patients with AML ineligible for induction have a dismal prognosis; hence disease stabilization is a primary treatment goal. This case of a 75-year-old patient with secondary AML receiving the combination of decitabine and ATRA (with
Externí odkaz:
https://doaj.org/article/6085df4c75ec4101b2942e2480228aaa
Autor:
Ruth Meier, Gabriele Greve, Dennis Zimmer, Helena Bresser, Bettina Berberich, Ralitsa Langova, Julia Stomper, Anne Rubarth, Lars Feuerbach, Daniel B. Lipka, Joschka Hey, Björn Grüning, Benedikt Brors, Justus Duyster, Christoph Plass, Heiko Becker, Michael Lübbert
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 8, Pp 1-13 (2022)
Abstract The prognosis of AML patients with adverse genetics, such as a complex, monosomal karyotype and TP53 lesions, is still dismal even with standard chemotherapy. DNA-hypomethylating agent monotherapy induces an encouraging response rate in thes
Externí odkaz:
https://doaj.org/article/3459f942a8ff4fc4b157fd33b7c8b1eb
Autor:
Silvia Waldeck, Jan Mitschke, Sebastian Wiesemann, Michael Rassner, Geoffroy Andrieux, Max Deuter, Jurik Mutter, Anne‐Marie Lüchtenborg, Daniel Kottmann, Laurin Titze, Christoph Zeisel, Martina Jolic, Ulrike Philipp, Silke Lassmann, Peter Bronsert, Christine Greil, Justyna Rawluk, Heiko Becker, Lisa Isbell, Alexandra Müller, Soroush Doostkam, Bernward Passlick, Melanie Börries, Justus Duyster, Julius Wehrle, Florian Scherer, Nikolas von Bubnoff
Publikováno v:
Molecular Oncology, Vol 16, Iss 2, Pp 527-537 (2022)
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non‐small‐cell lung cancer (NSCLC). However, little is known about its
Externí odkaz:
https://doaj.org/article/4399d10b1bd049f3a353a6cfadf469f6
Autor:
Christoph Rummelt, Olga Grishina, Claudia Schmoor, Martina Crysandt, Michael Heuser, Katharina S. Götze, Richard F. Schlenk, Konstanze Döhner, Helmut R. Salih, Gerhard Heil, Carsten Müller-Tidow, Wolfram Brugger, Andrea Kündgen, Maike de Wit, Aristoteles Giagounidis, Sebastian Scholl, Andreas Neubauer, Jürgen Krauter, Gesine Bug, Haifa Kathrin Al-Ali, Ralph Wäsch, Heiko Becker, Annette M. May, Justus Duyster, Björn Hackanson, Arnold Ganser, Hartmut Döhner, Michael Lübbert
Publikováno v:
Haematologica, Vol 108, Iss 8 (2023)
Externí odkaz:
https://doaj.org/article/3448ad0c720c4bd583057eb97a440fb5
Autor:
Severin Schmid, Heiko Becker, Ralph Fritsch, Johannes Bausch, Natalie Hunter, Carolin Jenkner, Mohamed Hassan, Bernward Passlick
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
This is a multicentre prospective randomised controlled trial for patients with 3 or more resectable pulmonary metastases from colorectal carcinoma. The study investigates the effects of pulmonary metastasectomy in addition to standard medical treatm
Externí odkaz:
https://doaj.org/article/443f7178d06c4efe9fe1a4368f122e16
Autor:
Christoph Niemöller, Julius Wehrle, Julian Riba, Rainer Claus, Nathalie Renz, Janika Rhein, Sabine Bleul, Juliane M. Stosch, Justus Duyster, Christoph Plass, Pavlo Lutsik, Daniel B. Lipka, Michael Lübbert, Heiko Becker
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-10 (2021)
Niemöller et al. describe a bisulfite-free assay to assess epigenomics and genomics of single cells (epi-gSCAR). epi-gSCAR generates accurate and reproducible measurements of global DNA methylation and genetic variants at the single cell level, allo
Externí odkaz:
https://doaj.org/article/cf2fb844146243e2a468922f8c181aef
Autor:
Shaima’a Hamarsheh, Lena Osswald, Benedikt S. Saller, Susanne Unger, Donatella De Feo, Janaki Manoja Vinnakota, Martina Konantz, Franziska M. Uhl, Heiko Becker, Michael Lübbert, Khalid Shoumariyeh, Christoph Schürch, Geoffroy Andrieux, Nils Venhoff, Annette Schmitt-Graeff, Sandra Duquesne, Dietmar Pfeifer, Matthew A. Cooper, Claudia Lengerke, Melanie Boerries, Justus Duyster, Charlotte M. Niemeyer, Miriam Erlacher, Bruce R. Blazar, Burkard Becher, Olaf Groß, Tilman Brummer, Robert Zeiser
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Oncogenic Ras mutations are common drivers in myeloid leukemia. Here, the authors show in patient cells and in mice that oncogenic K-Ras activates NLRP3 inflammasome to drive myeloproliferation, which can be reversed by genetic or pharmacologic NLRP3
Externí odkaz:
https://doaj.org/article/8d60e15645a540748f0978aece6a6bc5
Autor:
Ernst Mayerhofer, Christoph Strecker, Heiko Becker, Marios K. Georgakis, Md Mesbah Uddin, Michael M. Hoffmann, Niroshan Nadarajah, Manja Meggendorfer, Torsten Haferlach, Jonathan Rosand, Pradeep Natarajan, Christopher D. Anderson, Andreas Harloff, Gregor Hoermann
Publikováno v:
Stroke. 54:938-946
Background: Undetermined stroke etiology hampers optimal secondary prevention in a large proportion of young patients. We explored whether genetic screening for clonal hematopoiesis of indetermined potential (CHIP), a novel risk factor for stroke, co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82a37dc0bfc9a90451a7026b210a85d5
https://doi.org/10.1161/strokeaha.122.041416
https://doi.org/10.1161/strokeaha.122.041416